Vera Therapeutics Shares Gain on Positive Late-Stage Trial Results
By Connor HartShares of Vera Therapeutics climbed after the company said Trutakna, a treatment which helps mitigate the progression of certain kidney diseases, met all prespecified endpoints in a late-stage trial.The stock rose 9.8%, to $37.39, in premarket trading Tuesday. Through Monday's close…